• English
  • 简体中文
Login Register
Current Location: Home > Marketing Drugs(EU) Feedback Help
EMA Approvals
-
HMA Approvals
-

EMA:Drugs approved by European Medicines Agency through centralized Procedure. 

HMA:Drugs approved by EU members through Mutual Recognition Procedure.

For more information check in official website of members:

Drug label information in UK

Public Assessment Reports in UK

Marketed drugs in France

Marketed drugs in Italy

Marketed drugs in Switzerland

Marketed drugs in Sweden

Marketed drugs in Germany

Click here for more information

Brand name Nonproprietary Name Authorization date Marketing authorisation holder
Nexviadyme Avalglucosidase alfa 2022-06-24 Sanofi B.V.
Cabometyx cabozantinib 2016-09-09 Ipsen Pharma
Cometriq cabozantinib 2014-03-21 Ipsen Pharma
Bimervax COVID-19 Vaccine (recombinant, adjuvanted) 2023-03-30 Hipra Human Health S.L.
Upstaza eladocagene exuparvovec 2022-07-18 PTC Therapeutics International Limited
Vitrakvi larotrectinib 2019-09-19 Bayer AG
Elonva corifollitropin alfa 2010-01-25 N.V. Organon
Caelyx pegylated liposomal doxorubicin 1996-06-20 Baxter Holding B.V.
RotaTeq rotavirus vaccine, live 2006-06-26 Merck Sharp & Dohme B.V.
Dapagliflozin Viatris dapagliflozin 2023-03-24 Viatris Limited
Orgalutran ganirelix 2000-05-16 N.V. Organon
Briviact (in Italy: Nubriveo) brivaracetam 2016-01-13 UCB Pharma SA
RoActemra tocilizumab 2009-01-15 Roche Registration GmbH
Fuzeon enfuvirtide 2003-05-27 Roche Registration GmbH
COVID-19 Vaccine (inactivated, adjuvanted) Valneva COVID-19 vaccine (inactivated, adjuvanted, adsorbed) 2022-06-24 Valneva Austria GmbH
Thyrogen thyrotropin alfa 2000-03-09 Sanofi B.V.
Skyrizi risankizumab 2019-04-26 AbbVie Deutschland GmbH & Co. KG
Hepcludex bulevirtide 2020-07-31 Gilead Sciences Ireland UC
Myozyme alglucosidase alfa 2006-03-28 Sanofi B.V.
Tremelimumab AstraZeneca tremelimumab 2023-02-20 AstraZeneca AB